Skip to main content
Log in

Use of Over-the-Counter Analgesics in Patients with Chronic Liver Disease

Physicians’ Recommendations

  • Original Research Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Background: Over-the-counter analgesics (OTCAs), principally paracetamol (acetaminophen)-containing compounds and NSAIDs, are commonly used medications. Guidelines for the use of these agents in patients with chronic liver disease (CLD) are not available, despite the possibility that such patients may be more susceptible to the effects of an adverse reaction. Notwithstanding the lack of guidelines for healthcare providers, patients are often counselled to modify their use of these drugs. Therefore, the primary aim of this study was to assess healthcare providers’ recommendations on how OTCAs should be used by patients with CLD.

Methods: An 11-question web-based survey was distributed via email to healthcare providers participating in four healthcare networks in the US, to determine what recommendations they make to patients with cirrhosis (compensated and decompensated) and chronic hepatitis regarding the use of paracetamol and NSAIDs. Healthcare providers were also queried about the recommendations they make to patients with cirrhosis regarding pain control, and on the use of paracetamol for patients who consume alcohol daily.

Results: Overall, a 12% response rate was obtained. Internal medicine, family practice, paediatrics, and gastroenterology were the most represented practice types. Recommendations against the use of NSAIDs were significantly less common than recommendations against paracetamol use, in cases of both compensated and decompensated cirrhosis (p = 0.001). Non-gastroenterologists and non-primary care physicians were the least likely to recommend against NSAID use (p = 0.001), while gastroenterologists were the least likely to recommend against paracetamol in these patients (p = 0.001). It was the recommendation of most respondents that OTCAs should be avoided in patients with cirrhosis, and that paracetamol should be avoided or its dose reduced in the setting of daily alcohol use.

Conclusions: Significant variability exists among healthcare providers on their recommendations for OTCA use in the setting of chronic liver disease. Nongastroenterologists are more likely to recommend against the use of paracetamol than NSAIDs, and patients with chronic liver disease may be under-treated for pain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III
Table IV

Similar content being viewed by others

References

  1. Westphal JF, Brogard JM. Drug administration in chronic liver disease. Drug Saf 1997; 17: 47–73

    Article  PubMed  CAS  Google Scholar 

  2. Riley III TR, Bhatti AM. Preventive strategies in chronic liver disease: part I. Alcohol, vaccines, toxic medications and supplements, diet and exercise [published erratum appears in Am Fam Physician 2002; 65: 2438]. Am Fam Physician 2001; 64: 1555–60

    PubMed  Google Scholar 

  3. Ehrenpreis ED, Ehrenpreis S. Cytochrome P450: role in drug-induced hepatotoxicity. Clin Liver Dis 1998; 2: 457–70

    Article  Google Scholar 

  4. Benson GD. Acetaminophen in chronic liver disease. Clin Pharmacol Ther 1983; 33: 95–101

    Article  PubMed  CAS  Google Scholar 

  5. Farrell GC, Cooksley WG, Powell LW. Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes. Clin Pharmacol Ther 1979; 26: 483–92

    PubMed  CAS  Google Scholar 

  6. Sotaniemi EA, Pelkonen RO, Puukka M. Measurement of hepatic drug-metabolizing enzyme activity in man: comparison of three different assays. Eur J Clin Pharmacol 1980; 17: 267–74

    Article  PubMed  CAS  Google Scholar 

  7. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1991; 256: 1189–94

    PubMed  CAS  Google Scholar 

  8. Poulsen HE, Ranek L, Andreasen PB. The hepatic glutathione content in liver diseases. Scand J Clin Lab Invest 1981; 41: 573–6

    Article  PubMed  CAS  Google Scholar 

  9. Siegers CP, Bossen KH, Younes M, et al. Glutathione and glutathione-S-transferases in the normal and diseased human liver. Pharmacol Res Commun 1982; 14: 61–72

    Article  PubMed  CAS  Google Scholar 

  10. Amman R, Olsson R. Elimination of paracetamol in chronic liver disease. Acta Hepatogastroenterol (Stuttg) 1978; 25: 283–6 270

    Google Scholar 

  11. Dart RC, Kuffner EK, Rumack BH. Treatment of pain or fever with paracetamol (acetaminophen) in the alcoholic patient: a systematic review. Am J Ther 2000; 7: 123–34

    Article  PubMed  CAS  Google Scholar 

  12. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006; 296: 87–93

    Article  PubMed  CAS  Google Scholar 

  13. Carson JL, Willet LR. Toxicity of nonsteroidal anti-inflammatory drugs: an overview of the epidemiological evidence. Drugs 1993; 46 Suppl. 1: 243–8

    Article  PubMed  Google Scholar 

  14. Brater DC, Anderson SA, Brown-Cartwright D, et al. Effects of nonsteroidal antiinflammatory drugs on renal function in patients with renal insufficiency and in cirrhotics. Am J Kidney Dis 1986; 8: 351–5

    PubMed  CAS  Google Scholar 

  15. Zimmerman HJ. Acetaminophen hepatotoxicity. Clin Liver Dis 1998; 2: 523–41

    Article  Google Scholar 

  16. Larson AM, Poison J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42: 1364–72

    Article  PubMed  CAS  Google Scholar 

  17. Andreasen PB, Hutters L. Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. Acta Med Scand Suppl 1979; 624: 99–105

    PubMed  CAS  Google Scholar 

  18. Forrest JA, Clements JA, Prescott LF. Clinical pharmaco-kinetics of paracetamol. Clin Pharmacokinet 1982; 7: 93–107

    Article  PubMed  CAS  Google Scholar 

  19. Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther 2005; 12: 133–41

    Article  PubMed  Google Scholar 

  20. Claria J, Kent JD, Lopez-Parra M, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology 2005; 41: 579–87

    Article  PubMed  CAS  Google Scholar 

  21. Dargere S, Collet T, Crampon D, et al. Lack of toxicity of acetaminophen in patients with chronic hepatitis C: a randomized controlled trial [abstract]. Gastroenterology 2000; 118: A947

    Google Scholar 

  22. Kuffner EK, Dart RC, Bogdan GM, et al. Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001; 161: 2247–52

    Article  PubMed  CAS  Google Scholar 

  23. Leist MH, Gluskin LE, Payne JA. Enhanced toxicity of acetaminophen in alcoholics: report of three cases. J Clin Gastroenterol 1985; 7: 55–9

    Article  PubMed  CAS  Google Scholar 

  24. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure [published erratum appears in Hepatology 1995; 22: 1898]. Hepatology 1995; 22: 767–73

    Article  PubMed  CAS  Google Scholar 

  25. Tanaka E, Yamazaki K, Misawa S. Update: the clinical importance of acetaminophen hepatotoxicity in non-alcoholic and alcoholic subjects. J Clin Pharm Ther 2000; 25: 325–32

    Article  PubMed  CAS  Google Scholar 

  26. Rabinovitz M, Van Thiel DH. Hepatotoxicity of nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 1992; 87: 1696–704

    PubMed  CAS  Google Scholar 

  27. Gentilini P. Cirrhosis, renal function and NSAIDs. J Hepatol 1993; 19: 200–3

    Article  PubMed  CAS  Google Scholar 

  28. Arroyo V, Ginés P, Rimola A, et al. Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites: an overview with emphasis on pathogenesis. Am J Med 1986; 81: 104–22

    Article  PubMed  CAS  Google Scholar 

  29. Pérez-Ayuso RM, Arroyo V, Camps J, et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 1984; 26: 72–80

    Article  PubMed  Google Scholar 

  30. López-Parra M, Claria J, Planaguma A, et al. Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Br J Pharmacol 2002; 135: 891–900

    Article  PubMed  Google Scholar 

  31. Brater DC, Anderson SA, Brown-Cartwright D. Reversible acute decrease in renal function by NSAIDs in cirrhosis. Am J Med Sci 1987; 294: 168–74

    Article  PubMed  CAS  Google Scholar 

  32. Garcia Rodriguez LA, Williams R, Derby LE, et al. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994; 154: 311–6

    Article  PubMed  CAS  Google Scholar 

  33. Biskupiak JE, Brixner DI, Howard K, et al. Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. J Pain Palliat Care Pharmacother 2006; 20: 7–14

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this study. Simona Rossi, MD, and Victor J. Navarro, MD, have received research support from McNeil Consumer Products, the maker of Tylenol®. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Victor J. Navarro.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rossi, S., Assis, D.N., Awsare, M. et al. Use of Over-the-Counter Analgesics in Patients with Chronic Liver Disease. Drug-Safety 31, 261–270 (2008). https://doi.org/10.2165/00002018-200831030-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200831030-00007

Keywords

Navigation